A Stanford-led team has replaced toxic pre-transplant chemotherapy with a targeted antibody, allowing children with Fanconi anemia to receive stem cell transplants safely. The antibody, briquilimab, removes diseased stem cells without radiation, enabling nearly complete donor cell replacement. The approach also widens donor eligibility and could soon be applied to other bone marrow failure diseases.
source https://www.sciencedaily.com/releases/2025/11/251107010324.htm
Marquis blames ransomware breach on SonicWall cloud backup hack
-
Marquis Software Solutions, a Texas-based financial services provider, is
blaming a ransomware attack that impacted its systems and affected dozens
of U.S....
12 hours ago
No comments:
Post a Comment